Search

Displaying results 5641 - 5650 of 7452 in total
  1. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  2. Drug

    Amiloxate

    go.drugbank.com/drugs/DB11207
    Approved

    It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].

  3. Drug

    JNJ-64400141

    go.drugbank.com/drugs/DB24373
    Investigational

    JNJ-64400141 is under investigation in clinical trial NCT05242432 (A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory

  4. Drug

    Masitinib

    go.drugbank.com/drugs/DB11526
    InvestigationalVet approved

    In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

  5. Drug

    Utatrectinib

    go.drugbank.com/drugs/DB21295
    Investigational

    Utatrectinib is under investigation in clinical trial NCT01468324 (AZD7451 for Recurrent Gliomas). Utatrectinib has a monoisotopic molecular weight of 382.17 Da.

  6. Drug

    Talastine

    go.drugbank.com/drugs/DB13349
    Experimental

    Categories: Antihistamines for Systemic Use
  7. Drug

    Nicofetamide

    go.drugbank.com/drugs/DB13531
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  8. Drug

    Dimethylaminopropionylphenothiazine

    go.drugbank.com/drugs/DB13672
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  9. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.

  10. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.